Table 4 Characteristics and results of patients with slight progression in the control and study groups
Specifications of patients with slight progression NSP = 48 | Control group Before June 30, 2013 NCG = 23 | Study group After June 30, 2013 NSG = 25 | p |
|---|---|---|---|
Mean age, years ± SE | 62.87 ± 1.73 | 60.74 ± 1.52 | 0.358 |
Gender | |||
male | 17 (73.9%) | 22 (88.0%) | 0.190 |
female | 6 (26.1%) | 3 (12.0%) | |
MSKCC score, mean ± SE | 1.61 ± 0.1 | 1.60 ± 0.1 | 0.952 |
Number of metastatic sites, mean ± SE | 2.17 ± 0.24 | 2.36 ± 0.21 | 0.559 |
Location of metastases | |||
Lungs | 19 (82.6%) | 20 (80%) | 0.556 |
Bone | 7 (30.4%) | 9 (36%) | 0.460 |
Distant lymph node | 8 (34.8%) | 12 (48%) | 0.263 |
Liver | 3 (13%) | 4 (16%) | 0.549 |
Suprarenal gland | 1 (4.3%) | 3 (12%) | 0.337 |
Comorbidities | |||
Hypertension | 4 (17.4%) | 5 (20%) | 0.556 |
Other cardiovascular disorders | 2 (8.7%) | 3 (12%) | 0.541 |
Diabetes | 2 (8.7%) | 2 (8%) | 0.663 |
Secondary tumors | 0 | 1 | 0.521 |
Nephrectomy | |||
No | 6 (26.1%) | 0 (0.0%) | 0.008 |
Yes | 17 (73.9%) | 25 (100.0%) | |
Time from diagnosis to initiation of sunitinib | |||
< 1 year | 11 (47.8%) | 15 (60.0%) | 0.289 |
> 1 year | 12 (52.2%) | 10 (40.0%) | |
Hemoglobin level | |||
< normal range | 6 (26.1%) | 3 (12.0%) | 0.190 |
> normal range | 17 (73.9%) | 22 (88.0%) | |
Elevated corrected calcium level | |||
> 2.5 mmol/L | 2 (8.7%) | 1 (4.0%) | 0.468 |
< 2.5 mmol/L | 21 (91.3%) | 24 (96.0%) | |
Elevated LDH level | |||
> 1.5× normal level | 2 (8.7%) | 0 (0.0%) | 0.224 |
< 1.5× normal level | 21 (91.3%) | 25 (100.0%) | |
Elevated corrected calcium level | |||
> 2.5 mmol/L | 2 (8.7%) | 1 (4.0%) | 0.468 |
< 2.5 mmol/L | 21 (91.3%) | 24 (96.0%) | |
Karnofsky performance status | |||
< 80 | 0 (0.0%) | 1 (4.0%) | 0.521 |
≥ 80 | 23 (100.0%) | 24 (96.0%) | |
Dose reduction rate | |||
No | 10 (43.5%) | 16 (64.0%) | 0.226 |
Level 1 (37.5 mg) | 11 (47.8%) | 6 (24.0%) | |
Level 2 (25 mg) | 2 (8.7%) | 3 (12.0%) | |
Dose escalation rate | |||
No | 23 (100.0%) | 7 (28.0%) | < 0.001 |
Level 1 (62.5 mg) | 0 (0.0%) | 14 (56.0%) | |
Level 2 (75 mg) | 0 (0.0%) | 4 (16.0%) | |
Dosing scheme modification | |||
No | 19 (82.6%) | 18 (72.0%) | 0.300 |
Yes | 4 (17.4%) | 7 (28.0%) | |
Therapeutic lines after sunitinib 0 / 1 / 2 (%) | 6 (30) / 13 (65) / 1 (5) | 3 (15) / 13 (65) / 4 (20) | 0.247 |
mOS after sunitinib therapy | 9.33 ± 2.0 | 9.76 ± 2.5 | 0.599 |
mPFS | 14.2 ± 1.3 | 39.7 ± 5.1 | 0.037 |
mOS | 27.9 ± 2.5 | 57.5 ± 10.7 | 0.044 |
median follow-up time (range) (months) | 30.9 (11.2–89.5) | 45.7 (13.9–84.5) | 0.061 |